Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
about
Childhood Sjögren syndrome: insights from adults and animal modelsRituximab in primary Sjögren's syndrome: a ten-year journey.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Sjögren's syndrome in older patients: aetiology, diagnosis and management.Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.Biologic treatment in Sjögren's syndrome.Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.Effectiveness of Traditional Chinese Medicine Compound JieDuTongLuoShengJin Granules Treatment in Primary Sjögren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Safety of treatments for primary Sjögren's syndrome.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.The impact of primary Sjögren's syndrome on female sexual function.EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.Validation and psychometric properties of the Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) into Brazilian Portuguese.Management of primary Sjögren's syndrome: recent developments and new classification criteria.Effects of periodontal treatment on primary sjȫgren's syndrome symptoms.Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
P2860
Q33724868-0D057443-66B9-4C57-8B65-80766365680DQ34432465-0F725ED8-CA71-409A-9DFC-5F7DABB26ED8Q35774612-A4E02849-122A-4AF4-A753-58FFDA3DE80AQ38076070-7EC300E0-0846-421B-96C4-6691A4847D71Q38076460-A68C5B42-C55D-4DE0-8C08-B320A1B88527Q38262453-926DCE9B-1AAA-4855-90EF-93B616FDF060Q38437154-B8C50768-8B5A-41D8-BFD2-AD417BAC6E3DQ38645543-C72188B4-C9CC-48A6-AC5C-19B545152981Q38711144-D32D72B3-C26C-4899-81F5-40F2975DA9EAQ38795404-0B49CBCC-58C6-443F-B85C-3B6A07F80FC7Q39081726-3B616635-6F14-4FD2-A8F9-D0EF6F2EFC7DQ39791068-839FA80A-B37C-4794-B409-180248287741Q40117123-76E6F227-81C8-458C-99A2-FE70317DDAE8Q40383414-77AE1552-D7A5-48FF-83C4-B3940F5C76ACQ43462511-A4B5D13F-D343-4315-A1B2-A3371B66CC82Q43695088-FDE16C89-9A51-4728-BF8F-491BD4858886Q47381237-21DAEF8F-4969-4B0E-88B5-6490330FA6A0Q47700923-F12F7319-0860-4F11-8519-94E352CA4476Q47886685-89B87A2F-1410-4336-ACC4-3EF7B7620FC5Q48088375-5FD6D051-BE2A-428F-8402-38E02DAFA525Q50748403-6BB243F3-FF69-45D7-9B14-5392F3D60C0BQ52880103-D2185BA3-FC10-4ECC-A262-6DF46AB1D24A
P2860
Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Responsiveness of disease acti ...... ndrome treated with rituximab.
@en
Responsiveness of disease acti ...... ndrome treated with rituximab.
@nl
type
label
Responsiveness of disease acti ...... ndrome treated with rituximab.
@en
Responsiveness of disease acti ...... ndrome treated with rituximab.
@nl
prefLabel
Responsiveness of disease acti ...... ndrome treated with rituximab.
@en
Responsiveness of disease acti ...... ndrome treated with rituximab.
@nl
P2093
P1476
Responsiveness of disease acti ...... ndrome treated with rituximab.
@en
P2093
F K L Spijkervet
P M Meiners
P304
P356
10.1136/ANNRHEUMDIS-2011-200460
P407
P577
2012-01-17T00:00:00Z